Login to Your Account

Emisphere Crushed

Oral Calcitonin Market Wide Open for Tarsa After SMC021 Miss

By Jennifer Boggs
Managing Editor

Tuesday, November 15, 2011
Shares of Emisphere Technologies Inc. were walloped Monday after oral calcitonin candidate SMC021 failed to reduce the occurrence of new vertebral fractures in a three-year osteoporosis study, but the news could be a boon to a late-stage competitor.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription